A Phase 2 interventional study of PF-07868489 in Pulmonary Hypertension, sponsored by Pfizer. Terminated at 27 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 150 studies in Hypertension, Pulmonary with a site in Germany — 21 open to participants now, 28 under way, 6 of them phase 3. Hypertension, Pulmonary · Germany.
Among the 150 studies in Hypertension, Pulmonary with a site in Germany, this one is the 67th largest by enrollment of the 105 interventional ones that give a count, is one of 3 that started in 2025, is one of 36 in phase 2, and was the 143rd registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
Browse Hypertension, Pulmonary studies →21 of the 150 studies in Hypertension, Pulmonary with a site in Germany are open now. Recruiting first, the newest first:
Insmed Incorporated · Sites in Germany, United States, Czechia and 5 more countries
Ages 18+
Regeneron Pharmaceuticals · Sites in Germany, United States, Australia and 7 more countries
Ages 18+
Liquidia Technologies, Inc. · Sites in Germany, United States, Australia and 9 more countries
Ages 18–80
Insmed Incorporated · Sites in Germany, United States, Argentina and 27 more countries
Ages 18+
AllRock Bio, Inc. · Sites in Germany, United States, Australia and 6 more countries
Ages 18–80
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
150 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 40 · Phase 3 39 · Phase 4 2
First in 1993; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is above the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 86 across the 105 interventional studies, 394 across the 44 observational. Of the 105 that completed or were terminated, 47 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
86 of 150 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 7 studies filed under Hypertension, Pulmonary — fewer than ten, so there is no comparison to draw.
6 of the studies in Hypertension, Pulmonary with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06616974Tectonic TherapeuticA Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | 2026-11-24 |
| NCT05903001RWTH Aachen UniversityDiaphragmatic Function as a Biomarker | 2026-12-30 |
| NCT01347216Technische Universität DresdenCOMPERA / COMPERA-KIDS | 2026-12-31 |
| NCT07175038AllRock Bio, Inc.A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY) | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 150 studies in Hypertension, Pulmonary with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart.
This is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.
This study is seeking participants who are:
Participants will receive subcutaneous doses of PF-07868489 every 4 weeks
Drug: PF-07868489
Participants will receive subcutaneous doses of PF-07868489 every 4 weeks
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Baseline up to week 111
Number of Participants With Change From Baseline in Laboratory Tests Results
Time frame: Baseline up to week 111
Number of Participants With Vital Sign Abnormalities
Time frame: Baseline up to week 111
Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters
Time frame: Baseline up to week 111
Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration
Time frame: Baseline up to week 104
Minimum Observed Plasma Trough Concentration (Cmin), as data permits
Time frame: Baseline up to week 111
Incidence of Anti-Drug Antibody (ADA)
Time frame: Baseline up to week 111
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Nov 2025 to primary completion in Oct 2026, 10 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Aug 2028 → Oct 2026 and completion Aug 2028 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.
The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.